Published • loading... • Updated
Dispatch Bio Reports Preclinical Cancer Therapy Data
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Dispatch Bio Reports Preclinical Cancer Therapy Data
PHILADELPHIA, PA — Dispatch Bio said it will present new preclinical data on its SEND T cell engineering platform at the ASGCT 2026 Annual Meeting, highlighting experimental results showing anti-tumor activity in solid tumor models. The company said the findings involve SEND, short for Synthetic Efficacy eNableD, a synthetic cytokine receptor platform designed to activate multiple T cell signaling pathways simultaneously. According to Dispatch B…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
